Different modulation of Panax notoginseng on the absorption profiling of triptolide and tripterine from Tripterygium wilfordii in rat intestine
Tóm tắt
Compatibility with Panax notoginseng (PN) reduced the plasma concentration of triptolide and delayed the Tmax of Tripterygium wilfordii (TW), the sovereign medicine of Qing-Luo Tong-Bi decoction, which hinted the absorption process of triptolide might
be involved in decreasing the toxicity in liver and kidney. The absorption of triptolide, triptonide, wilforlide and tripterine from monomer, TW, TW-PN, TW-Caulis Sinomenii (TW-CS) and Qing-Luo Tong-Bi were analyzed in duodenum, jejunum, ileum and colon of rat via single-pass intestinal perfusion model. An UPLC-MS/MS analysis method was developed to determine the concentration of triptolide, triptonide, wilforlide and tripterine in the inlet and outlet. Then Peff, 10 cm%ABS and Ka were calculated based on the perfusate flux, perfusate volume and candidate chemicals concentration. The absorption of triptolide, triptonide, wilforlide and tripterine in duodenum, jejunum, ileum and colon was independent of concentration within range of 3–9 μg/mL. The target compounds, triptolide, triptonide, wilforlide and tripterine from the TW extract, showed higher absorption extent and rate than those administrated alone, and compared with the absorption situation of the chemicals of TW extract, the absorption of triptolide, triptonide and wilforlide of the extract of TW-PN, TW-CS and Qing-Luo Tong-Bi were decreased in these intestinal segments. However, PN-promoted tripterine absorption was observed in the intestine. Modulation of absorption of chemicals in TW by subsidiary herbs may be responsible for reinforcing the actions and neutralizing the adverse effects through compatibility in the formula of Qing-Luo Tong-Bi. PN inhibits the absorption of triptolide of TW and promote the absorption of tripterine.
Tài liệu tham khảo
Li Y, Wang J, Xiao Y, et al. A systems pharmacology approach to investigate the mechanisms of action of Semen Strychni and Tripterygium wilfordii Hook F for treatment of rheumatoid arthritis. J Ethnopharmacol. 2015;175:301–14.
Zhang Y, Xu W, Li H, et al. Therapeutic effects of total alkaloids of Tripterygium wilfordii Hook f. on collagen-induced arthritis in rats. J Ethnopharmacol. 2013;145:699–705.
Li J, Shen F, Guan C, et al. Activation of Nrf2 protects against triptolide-induced hepatotoxicity. PLoS ONE. 2014;9:e100685.
Ma J, Dey M, Yang H, et al. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry. 2007;68:1172–8.
Li XX, Du FY, Liu HX, et al. Investigation of the active components in Tripterygium wilfordii leading to its acute hepatotoxicity and nephrotoxicity. J Ethnopharmacol. 2015;162:238–43.
Zhang B, Zhang Q, Liu M, et al. Increased involvement of Panax notoginseng in the mechanism of decreased hepatotoxicity induced by Tripterygium wilfordii in rats. J Ethnopharmacol. 2016;185:243–54.
Liang XL, Liao ZG, Zhu JY, et al. The absorption characterization effects and mechanism of Radix Angelicae dahuricae extracts on baicalin in Radix Scutellariae using in vivo and in vitro absorption models. J Ethnopharmacol. 2012;139:52–7.
Fagerholm U, Lindahl A, Lennernas H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol. 1997;49:687–90.
Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1996;13:1336–42.
Salphati L, Childers K, Pan L, et al. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol. 2001;53:1007–13.
Nie SF, Pan WS, Yang XG, et al. Evaluation of gravimetry in the rat single-pass intestinal perfusion technique. Chin J New Drugs. 2005;14:1176–9.
Huang SH, Long XY, Yuan F, et al. Transport of puerarin in rat intestine in situ by modified gravimetry and phenol red assay. J Guangdong Pharm Univ. 2012;28:603–7.
Varma MV, Obach RS, Rotter C, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53:1098–108.
Sugano K, Terada K. Rate- and extent-limiting factors of oral drug absorption: theory and applications. J Pharm Sci. 2015;104:2777–88.
Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
Oshima T, Miwa H. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol. 2016;51:768–78.
Anzai K, Fukagawa K, Iwakiri R, et al. Increased lipid absorption and transport in the small intestine of zucker obese rats. J Clin Biochem Nutr. 2009;45:82–5.
Terato K, Hiramatsu Y, Yoshino Y. Studies on iron absorption. II. Transport mechanism of low molecular iron chelate in rat intestine. Am J Dig Dis. 1973;18:129–34.
Mahmud F, Jeon OC, Al-Hilal TA, et al. Absorption mechanism of a physical complex of monomeric insulin and deoxycholyl-l-lysyl-methylester in the small intestine. Mol Pharm. 2015;12:1911–20.
Zhai L, Shi J, Xu W, et al. Ex vivo and in situ evaluation of ‘dispelling-wind’ Chinese medicine herb–drugs on intestinal absorption of chlorogenic acid. Phytother Res. 2015;29:1974–81.
Dahan A, Amidon GL. MRP2 mediated drug–drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm. 2010;386:216–20.
Hackam DJ. Guts, germs and glucose: understanding the effects of prematurity on the interaction between bacteria and nutrient absorption across the intestine. Br J Nutr. 2012;108:571–3.
Martinez-Montano E, Pena E, Viana MT. Intestinal absorption of amino acids in the Pacific bluefin tuna (Thunnus orientalis): in vitro lysine–arginine interaction using the everted intestine system. Fish Physiol Biochem. 2013;39:325–34.
Hassan IA, Elzubeir EA, El Tinay AH. Growth and apparent absorption of minerals in broiler chicks fed diets with low or high tannin contents. Trop Anim Health Prod. 2003;35:189–96.
Mao X, Wu LF, Zhao HJ, et al. Transport of corilagin, gallic acid, and ellagic acid from Fructus phyllanthi tannin fraction in Caco-2 cell monolayers. Evid Based Complement Altern Med. 2016;2016:9205379.
Jamroz D, Wiliczkiewicz A, Skorupinska J, et al. Effect of sweet chestnut tannin (SCT) on the performance, microbial status of intestine and histological characteristics of intestine wall in chickens. Br Poult Sci. 2009;50:687–99.
He X, Deng FJ, Ge JW, et al. Effects of total saponins of Panax notoginseng on immature neuroblasts in the adult olfactory bulb following global cerebral ischemia/reperfusion. Neural Regen Res. 2015;10:1450–6.
Kim SW, Kwon HY, Chi DW, et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol. 2003;65:75–82.
Drescher S, Glaeser H, Murdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003;73:223–31.
Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008;4:923–39.
Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13:129–34.
Kuze J, Mutoh T, Takenaka T, et al. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam. Xenobiotica. 2013;43:598–606.
Schurgers N, Bijdendijk J, Tukker JJ, et al. Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ. J Pharm Sci. 1986;75:117–9.
Takara K, Ohnishi N, Horibe S, et al. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab Dispos. 2003;31:1235–9.
Van Peer E, Verbueken E, Saad M, et al. Ontogeny of CYP3A and P-glycoprotein in the liver and the small intestine of the Gottingen minipig: an immunohistochemical evaluation. Basic Clin Pharmacol Toxicol. 2014;114:387–94.
Singhal D, Ho NF, Anderson BD. Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2′,3′-dideoxyinosine in the mesenteric vein cannulated rat ileum. J Pharm Sci. 1998;87:569–77.
Suarez-Sharp S, Li M, Duan J, et al. Regulatory experience with in vivo in vitro correlations (IVIVC) in new drug applications. AAPS J. 2016;18:1379–90. https://doi.org/10.1208/s12248-016-9966-2.
Lu Y, Kim S, Park K. In vitro-in vivo correlation: perspectives on model development. Int J Pharm. 2011;418:142–8.
